Krishna Institute of Medical SciencesQ4 FY24

Krishna Institute of Medical Sciences Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹768.3P/E: 158.8Market Cap: ₹32.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • KIMS expects a steady revenue growth of around 10% year-on-year for mature hospitals and clusters like Telangana and Andhra Pradesh (AP), driven by volume growth, price hikes, and case mix improvements.
  • Volume growth in AP inpatient services is around 6%, with overall cluster growth aided by new specialties and bed additions.
  • New bed capacity additions, e.g., 100 incremental beds in Kondapur Phase 1 by Q1 FY '26 and full 500-550 beds by Q1 FY '27, are expected to boost revenue.
  • The ramp-up of new doctors, especially in Telangana and AP clusters, is expected to accelerate growth reaching around 15-20% in some quarters.
  • Sunshine and Nagpur hospitals are showing encouraging growth with plans for revenue expansion and margin improvement.
  • Pricing adjustments with insurance companies, including a potential 20-30% hike from GIPSA, will contribute to revenue growth.
  • Overall, KIMS targets a consistent 10% revenue growth with occasional higher growth during capacity expansions.

See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No explicit mention of any immediate new fundraising through debt or equity in the transcript.
  • Current capex for FY24 was around INR 650 crores, FY25 anticipated INR 400-600 crores, funded through existing debt and internal accruals.
  • Debt levels have increased mainly due to acquisitions and ongoing projects like Thane, Bangalore, Nashik; total debt still being managed within a debt-equity target of 0.7 and debt-EBITDA of 1.5.
  • Management emphasizes disciplined capital deployment with preference for asset-light O&M (operations and management) contracts with buyback options to limit capital infusion.
  • Future debt repayment expected after FY26 as existing projects stabilize; no indication of additional fundraise planned before then.
  • The company appears focused on controlling leverage rather than raising new equity or debt in the near term.

See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY24 capex incurred was approximately INR 650 crore, including land and building at Thane.
  • FY25 anticipated capex is between INR 400 crore and INR 600 crore.
  • Key projects include Bangalore (2 hospitals: 450-bed Marathahalli and 300-bed South Bangalore), Thane, Nashik, and Kondapur expansions.
  • Bangalore hospital (Marathahalli) cost ~INR 1 crore/bed; South Bangalore hospital is on a revenue-share model with INR 70-80 lakh/bed.
  • Thane hospital total capex expected around INR 515 crore, with potential to add 150 beds in Phase 2 at lower cost.
  • Kondapur expansion divided into two phases: incremental 100 beds commissioned early FY26 and full 500-550 beds by Q1 FY27.
  • Strategy favors asset-light models and partnerships to limit capital commitment.
  • Debt repayments expected to start post FY26 with target debt-to-equity of 0.7 and debt-to-EBITDA of 1.5.

Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed

How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?

Pro feature
ThisKrishna Institute of Medical Sciences
Rev 3Mar 3

How does Krishna Institute of Medical Sciences rank in Healthcare Services?

Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →